Theratechnologies Inc Financials

Theratechnologies Inc (THTX) reported $85.9M in total revenue for fiscal year 2024. This represents a 5.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Theratechnologies Inc (THTX) revenue grew by 5% year-over-year, from $81.8M to $85.9M in fiscal year 2024.

No, Theratechnologies Inc (THTX) reported a net income of -$8.3M in fiscal year 2024, with a net profit margin of -9.7%.

As of fiscal year 2024, Theratechnologies Inc (THTX) had $15.9M in cash and equivalents against $791K in long-term debt.

Theratechnologies Inc (THTX) had a net profit margin of -9.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Theratechnologies Inc (THTX) generated $2.4M in free cash flow during fiscal year 2024. This represents a 139.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Theratechnologies Inc (THTX) generated $2.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Theratechnologies Inc (THTX) had $53.3M in total assets as of fiscal year 2024, including both current and long-term assets.

Theratechnologies Inc (THTX) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Theratechnologies Inc (THTX) had 46M shares outstanding as of fiscal year 2024.

Theratechnologies Inc (THTX) had a current ratio of 1.19 as of fiscal year 2024, which is considered adequate.

Theratechnologies Inc (THTX) had a debt-to-equity ratio of -0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Theratechnologies Inc (THTX) had a return on assets of -15.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Theratechnologies Inc (THTX) has negative shareholder equity of -$25.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Theratechnologies Inc (THTX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Theratechnologies Inc (THTX) has an earnings quality ratio of -0.29x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.